Lv21
200 积分 2021-06-09 加入
Oteseconazole
1个月前
已完结
Oteseconazole: First Approved Orally Bioavailable and Selective CYP51 Inhibitor for the Treatment of Patients with Recurrent Vulvovaginal Candidiasis
1个月前
已完结
Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis: A Drug Review
1个月前
已完结
Oteseconazole: a long-awaited diversification of the antifungal arsenal to manage recurrent vulvovaginal candidiasis (RVVC)
1个月前
已完结
Design and optimization of highly-selective fungal CYP51 inhibitors
1个月前
已完结
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis
1个月前
已完结
Strategies of targeting CYP51 for IFIs therapy: Emerging prospects, opportunities and challenges
1个月前
已完结
Tirzepatide Once Weekly for the Treatment of Obesity
1个月前
已完结
Emerging therapeutic options for refractory gout
1年前
已采纳
2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure
3年前
已采纳
A cell-based high-throughput screen identifies drugs that cause bleeding disorders by off-targeting the vitamin K cycle
4年前
已采纳
Macrophage-Inducible C-Type Lectin Signaling Exacerbates Acetaminophen-Induced Liver Injury by Promoting Kupffer Cell Activation in Mice
4年前
已驳回
Application of mesenchymal stem cell therapy for the treatment of osteoarthritis of the knee: A concise review
4年前
已采纳
皖公网安备34019202002308
